Promising Cellular Immunotherapy for Colorectal Cancer Using Classical Dendritic Cells and Natural Killer T Cells
Cells · 22.01.2025 · 14 (3) · 166
DOI: 10.3390/cells14030166 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 22.01.2025. Verfasst von Mahmoud Singer und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiological Sciences, School of Medicine, University of California, Irvine, CA 92617, USA. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Dendritic Cells, Immunotherapy, Natural Killer T-Cells. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 198 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Colorectal cancer (CRC) remains one of the leading causes of cancer-related morbidity and mortality around the world. Despite advances in surgery, chemotherapy, and targeted therapies, the prognosis for patients with metastatic or advanced CRC remains poor. Immunotherapies comprising immune checkpoint inhibitors showed disappointing responses in metastatic CRC (mCRC). However, cellular immunotherapy, specifically using classical dendritic cells (cDCs), may hold unique promise in immune recognition for CRC antigens. cDCs are substantial players in immune recognition and are instrumental in orchestrating innate and adaptive immune responses by processing and presenting tumor antigens to effector cells. Natural killer T (NKT) cells are insufficiently studied but unique effector cells because of their ability to bridge innate and adaptive immune reactions and the crosstalk with dendritic cells in cancer. This review explores the therapeutic potential of using both cDCs and NKT cells as a synergistic therapy in CRC, focusing on their biological roles, strategies for harnessing their capabilities, clinical applications, and the challenges within the tumor microenvironment. Both cDCs and NKT cells can be used as a new effective approach for cell-based therapies in cancers to provide a new hope for CRC patients that are challenging to treat.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiological Sciences, School of Medicine, University of California, Irvine, CA 92617, USA.
- Department of Medicine, Chao Family Comprehensive Cancer Center, University of California, Irvine, CA 92697, USA.
- Department of Surgery, University of California Irvine, Orange, CA 92697, USA.
ORCID-Profile: Mahmoud Singer, Farshid Dayyani, April Choi, David Imagawa, Nadine Abi-Jaoudeh
Förderung
- NCI NIH HHS
Zitieren
APA
Singer, M., Valerin, J., Zhang, Z., Zhang, Z., Dayyani, F., Yaghmai, V., Choi, A., Imagawa, D., & Abi-Jaoudeh, N. (2025). Promising Cellular Immunotherapy for Colorectal Cancer Using Classical Dendritic Cells and Natural Killer T Cells. Cells, 14(3), 166. https://doi.org/10.3390/cells14030166
Vancouver
Singer M, Valerin J, Zhang Z, Zhang Z, Dayyani F, Yaghmai V, et al. Promising Cellular Immunotherapy for Colorectal Cancer Using Classical Dendritic Cells and Natural Killer T Cells. Cells. 2025;14(3):166. doi:10.3390/cells14030166
BibTeX
@article{Singer2025,
author = {Singer, Mahmoud and Valerin, Jennifer and Zhang, Zhuoli and Zhang, Zigeng and Dayyani, Farshid and Yaghmai, Vahid and Choi, April and Imagawa, David and Abi-Jaoudeh, Nadine},
title = {Promising Cellular Immunotherapy for Colorectal Cancer Using Classical Dendritic Cells and Natural Killer T Cells},
journal = {Cells},
year = {2025},
volume = {14},
number = {3},
pages = {166},
doi = {10.3390/cells14030166}
}
EUVIMED